Hormonal
Skeletal muscle aging independently increases the risk of insulin resistance through a convergence of mitochondrial dysfunction, intramyocellular lipid accumulation, chronic inflammation, oxidative stress, and sarcopenia.
As you age, your muscles naturally become less efficient at processing glucose due to cellular stress and inflammation. To counter this, prioritize resistance training and aerobic exercise, which directly improve mitochondrial function and reduce inflammation, thereby preserving your insulin sensitivity despite aging.
These changes can impair skeletal muscle insulin sensitivity and increase the risk of insulin resistance and type 2 diabetes during skeletal muscle aging.
Why this rating
This is a review paper citing multiple observational and animal studies; it synthesizes evidence rather than presenting new primary clinical trial data.
Source
Mechanism of increased risk of insulin resistance in aging skeletal muscle
Jian Shou et al. · Diabetology & Metabolic Syndrome · 2020
DOI 10.1186/s13098-020-0523-x
More from this paper
- Exercise acts as a non-pharmacological intervention that counteracts age-related insulin resistance by enhancing mitochondrial oxidative capacity, improving autophagy, and reducing oxidative stress and inflammation.Good
- Mitochondrial dysfunction in aging skeletal muscle, characterized by reduced oxidative capacity and increased ROS production, directly impairs insulin signaling and promotes insulin resistance.Moderate
- Intramyocellular lipid (IMCL) accumulation, specifically the buildup of ceramides and diacylglycerol (DAG), impairs insulin signaling by activating inflammatory pathways and interfering with Akt activity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →